AstraZeneca Acquires Modella AI to Accelerate Cancer Therapy Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Acquisition Strategy: AstraZeneca's acquisition of biomedical AI company Modella AI aims to accelerate cancer therapy development by leveraging Modella AI's multi-modal foundation models and AI agents to enhance the generation of biological and clinical insights.
- R&D Efficiency Boost: This acquisition will enable AstraZeneca to achieve greater automation, scalability, and consistency in its oncology R&D, optimizing data-intensive workflows and improving the quality and efficiency of research outcomes.
- Historical Collaboration: AstraZeneca has been collaborating with Modella AI since July 2025 under a multi-year agreement, and this acquisition signifies a deepening of their partnership, highlighting AstraZeneca's commitment to the potential of AI technology in cancer treatment.
- Market Impact: Although financial details were not disclosed, this acquisition is expected to strengthen AstraZeneca's competitive position in oncology, enhancing its leadership in the rapidly evolving biopharmaceutical market.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 99.67 USD with a low forecast of 95.00 USD and a high forecast of 103.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 96.340
Low
95.00
Averages
99.67
High
103.00
Current: 96.340
Low
95.00
Averages
99.67
High
103.00
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
